NCT07607119 PULSAR Combined With Immunotherapy for Unresectable Locally Advanced Gastric Cancer
| NCT ID | NCT07607119 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Samsung Medical Center |
| Condition | Gastric Adenocarcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 53 participants |
| Start Date | 2026-05-15 |
| Primary Completion | 2028-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 53 participants in total. It began in 2026-05-15 with a primary completion date of 2028-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this prospective, single-center, phase II study is to evaluate the clinical efficacy and safety of combining first-line systemic therapy plus immunotherapy with personalized ultrafractionated stereotactic adaptive radiation therapy (PULSAR) in patients with unresectable locally advanced gastric cancer.
Eligibility Criteria
Inclusion Criteria: Age 19 or more years. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2. Histologically confirmed gastric adenocarcinoma. Tumor biomarker status: HER-2 negative, EBV negative, and Microsatellite Stable (MSS). Unresectable, locally advanced extent at initial staging (Para-aortic lymph node \[PALN\] and Supraclavicular lymph node \[SCN\] metastases are allowed). Has completed 3 or more cycles of first-line systemic therapy combined with immunotherapy without evidence of disease progression. Presence of at least one evaluable lesion according to RECIST v1.1 that is deemed safely irradiable by the investigator. Voluntary written informed consent provided by the subject. Exclusion Criteria: Pregnant or lactating women. Presence of brain metastases or leptomeningeal involvement. Prior history of radiation therapy to the intended target site. Severe uncontrolled comorbidities that, in the investigator's opinion, limit study participation or treatment compliance (e.g., uncontrolled infection, heart failure, arrhythmia, psychiatric illness). Inability or unwillingness to comply with the study protocol procedures. Any condition deemed inappropriate for study participation by the principal investigator or attending physician.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07607119 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Gastric Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07607119 currently recruiting?
Yes, NCT07607119 is actively recruiting participants. Contact the research team at ro.yuji651@gmail.com for enrollment information.
Where is the NCT07607119 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT07607119 clinical trial?
NCT07607119 is sponsored by Samsung Medical Center. The trial plans to enroll 53 participants.